Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores-Reference-Cited by-同舟云学术

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Published:2020-05-15 Issue:8 Volume:69 Page:1545-1547
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Targher Giovanni^ORCID,Mantovani Alessandro,Byrne Christopher D,Wang Xiao-Bo,Yan Hua-Dong,Sun Qing-Feng,Pan Ke-Hua,Zheng Kenneth I^ORCID,Chen Yong-Ping,Eslam Mohammed,George Jacob^ORCID,Zheng Ming-Hua^ORCID

Publisher

BMJ

Subject

Gastroenterology

Reference10 articles.

1. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study;Ji;J Hepatol,2020

2. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease;Eslam;Gastroenterology,2020

3. Non-alcoholic fatty liver disease - A global public health perspective;Younossi;J Hepatol,2019

4. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis;Taylor;Gastroenterology,2020

5. Gao F , Zheng KI , Wang XB , et al . Obesity as a risk factor for greater severity of COVID-19. Diabetes Care 2020.

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy;PLOS ONE;2024-05-07

2. Is Steatotic Liver Disease Related to Poor Outcome in COVID-19-Hospitalized Patients?;Journal of Clinical Medicine;2024-05-03

3. MAFLD as part of systemic metabolic dysregulation;Hepatology International;2024-04-09

4. Metabolic abnormalities in patients with non-alcoholic fatty liver disease with immune response to SARS-CoV-2;GASTROENTEROLOGY;2024-04-07

5. Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial;Hepatology;2024-03-27